Literature DB >> 18926539

Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.

Naoto Katakami1, Munehide Matsuhisa, Hideaki Kaneto, Taka-aki Matsuoka, Ken'ya Sakamoto, Tetsuyuki Yasuda, Yutaka Umayahara, Keisuke Kosugi, Yoshimitsu Yamasaki.   

Abstract

OBJECTIVE: Advanced glycation end-products (AGEs) and the receptor for AGEs (RAGE) system plays an important role in the development of atherosclerosis. It has been recently reported that endogenous secretory RAGE (esRAGE) and total soluble RAGE (sRAGE) levels are associated with diabetic complications. The aim of the present study is to longitudinally evaluate the association between esRAGE and sRAGE levels and the progression of carotid intima-media thickness (IMT), a surrogate marker of atherosclerosis. METHODS AND
RESULTS: Japanese type 1 diabetic patients (n=47, aged 24.0+/-3.1 years) were enrolled into a 4-year follow-up study and annual measurements of serum esRAGE and sRAGE levels and IMTs were performed. At baseline, mean-IMT was inversely correlated with circulating esRAGE levels (r=-0.317, p=0.0292), whereas there was not statistical significance between mean-IMT and sRAGE levels. Mean-IMT significantly increased during the follow-up period (from 0.63+/-0.10 to 0.67+/-0.10mm, p=0.0022). Annual increase in mean-IMT (=(mean-IMT after 4 years-mean-IMT at baseline)/4) was positively correlated with the arithmetic average of systolic blood pressure (r=0.310, p=0.0332) and triglyceride (r=0.337, p=0.0201), and inversely correlated with circulating esRAGE levels (r=-0.360, p=0.0124) and sRAGE levels (r=-0.406, p=0.0042) during the follow-up period. Furthermore, stepwise multivariate regression analyses revealed that continuous low levels of circulating esRAGE and sRAGE were determinants of the progression of mean-IMT independently of conventional risk factors.
CONCLUSIONS: Circulating esRAGE level as well as sRAGE level was an independent risk factor for the progression of carotid IMT in type 1 diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926539     DOI: 10.1016/j.atherosclerosis.2008.08.026

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  29 in total

1.  Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS).

Authors:  Barry I Hudson; Yeseon Park Moon; Anastasia Z Kalea; Minesh Khatri; Chensy Marquez; Ann Marie Schmidt; Myunghee C Paik; Mitsuhiro Yoshita; Ralph L Sacco; Charles DeCarli; Clinton B Wright; Mitchell S V Elkind
Journal:  Atherosclerosis       Date:  2011-01-21       Impact factor: 5.162

2.  The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood.

Authors:  Cosimo Giannini; Ebe D'Adamo; Tommaso de Giorgis; Valentina Chiavaroli; Alberto Verrotti; Francesco Chiarelli; Angelika Mohn
Journal:  Pediatr Nephrol       Date:  2011-08-26       Impact factor: 3.714

3.  Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea.

Authors:  W Cai; J-F Sun; Y Liu; J-X Xu; J-R Xiao; X-M Duan; J-Y Liu; W Zhang
Journal:  J Hum Hypertens       Date:  2015-05-21       Impact factor: 3.012

4.  Serum soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS).

Authors:  Barry I Hudson; Hannah Gardener; Wen Liu-Mares; Chuanhui Dong; Ken Cheung; Mitchell S V Elkind; Clinton B Wright; Ralph L Sacco; Tatjana Rundek
Journal:  Atherosclerosis       Date:  2015-02-24       Impact factor: 5.162

5.  Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients.

Authors:  Mohamed M Nasrallah; Amal R El-Shehaby; Noha A Osman; Mona M Salem; Amr Nassef; Usama A A Sharaf El Din
Journal:  Int Urol Nephrol       Date:  2011-06-04       Impact factor: 2.370

Review 6.  When are type 1 diabetic patients at risk for cardiovascular disease?

Authors:  Trevor J Orchard; Tina Costacou
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

7.  Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.

Authors:  Y Yu; K F Hanssen; V Kalyanaraman; A Chirindel; A J Jenkins; A J Nankervis; P A Torjesen; H Scholz; T Henriksen; B Lorentzen; S K Garg; M K Menard; S M Hammad; J A Scardo; J R Stanley; M Wu; A Basu; C E Aston; T J Lyons
Journal:  BJOG       Date:  2012-08-20       Impact factor: 6.531

8.  Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study.

Authors:  J W M Nin; I Ferreira; C G Schalkwijk; M H Prins; N Chaturvedi; J H Fuller; C D A Stehouwer
Journal:  Diabetologia       Date:  2009-01-30       Impact factor: 10.122

9.  Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.

Authors:  Johanna W M Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D A Stehouwer
Journal:  Diabetes       Date:  2010-06-03       Impact factor: 9.461

Review 10.  Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Biochem Pharmacol       Date:  2010-01-22       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.